• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Accu-Chek infusion set recalled


Roche recently recalled its Accu-Chek FlexLink Plus infusion sets globally because they may under-deliver insulin to patients.

Roche recently recalled its Accu-Chek FlexLink Plus infusion sets globally because they may under-deliver insulin to patients.

Some customers reported a kinked or bent tube when inserting the infusion set. “If this remains unnoticed it can result in under-delivery, leading to elevation of blood glucose levels,” said Todd Siesky, spokesman for Roche Diabetes Care. Fourteen adverse events related to the bent tube had been reported to FDA at the time of recall, according to Siesky.

More than 140,000 ACCU-CHEK FlexLink Plus infusion sets have been recalled in the United States. Siesky did not know how many sets have been recalled globally. ACCU-CHEK FlexLink Plus was launched in November 2010, and is sold directly to patients via distributors.

Other Accu-Chek infusion sets and insulin pumps are not affected by the recall and can continue to be used by patients.

Patients should return the Accu-Chek FlexLink Plus sets to their healthcare providers or caregivers. Adverse events should be reported to FDA’s MedWatch Safety Information and Adverse Reporting program at www.fda.gov/MedWatch, or call (800) 332-1088.

Related Videos
Video 6 - "Failing to Reach Ideal Diabetes Care: Equitable Doesn’t Mean Equal"
Video 5 - "Revising Diabetes Outcome Measures"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 8 - "Demographic Differences That Impact Care"
Video 7 - "Gaps in Diabetes Education and Self Efficacy"
Video 6 - "Key Takeaways and Unmet Needs in Diabetes Treatment"
Video 5 - "Allocation of Investment and Value-Based Arrangements in Diabetes Care "
Video 3 - "Integrating CGMs into Diabetes Treatment Programs"
Video 2 - "Identifying Inequities in CGM Access"
Related Content
© 2024 MJH Life Sciences

All rights reserved.